Staphylococcus aureus Network Adaptive Platform trial (SNAP)

Phase 1

Recruiting

Conditions: Staphylococcus aureus bacteremia
Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]

Registration Number: CTIS2023-503582-35-00

Lead Sponsor: niversity Medical Center Utrecht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 1348

Inclusion Criteria

Staphylococcus aureus complex grown from =1 blood culture, Admitted to a participating hospital at the time of eligibility assessment (OR if patient has died, they were admitted to this site anytime from the time of blood culture collection until the time of eligibility assessment)

Exclusion Criteria

Time of anticipated platform entry is greater than 72 hours post collection of the index blood culture, Polymicrobial bacteraemia, defined as more than one organism (at species level) in the index blood cultures OR in any subsequent blood culture reported between the collection of the index blood culture and platform eligibility assessment, excluding those organisms judged to be contaminants by either the microbiology laboratory or treating clinician, Known previous participation in the randomised SNAP platform, Known positive blood culture for S. aureus (of the same silo: PSSA, MSSA or MRSA) between 72 hours and 180 days prior to the time of eligibility assessment, Treating team deems enrolment in the study is not in the best interest of the patient, Treating team believes that death is imminent and inevitable, Patient is for end-of-life care and antibiotic treatment is considered not appropriate, Patient has died since the collection of the index blood culture

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: To examine the effect on all-cause mortality at 90 days of a range of interventions in patients with SAB;Secondary Objective: Examining the effect of a range of interventions on several secondary endpoints including mortality, hospital length of stay, treatment failure, treatment complications, and healthcare costs.;Primary end point(s): all-cause mortality at 90 days after platform entry

Secondary Outcome Measures